| Species |
Human |
| Protein Construction |
HLA-A*02:01&B2M&CMV pp65 (NLVPMVATV) Monomer [Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and NLVPMVATV peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&NLVPMVATV |
His |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.35 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Human cytomegalovirus (CMV) is one of the major causes of severe complications in immunocompromised patients, such as recipients of hematopoietic cells, solid organ transplantation, and HIV-infected individuals. CMV is also a major pathogen in congenital infection. It can cause life-threatening diseases and severe neurological sequelae in new born infants. CMV phosphoprotein pp65 is thought to be a major antigen for CMV-specific cellular immunity. |
| Synonyms |
MHC; HLA-A*02:01; CMV pp65 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
